Concord Biotech Limited has informed the Exchange regarding Appointment of Mrs. Ekta Gupta as Independent Director of the company w.e.f. Jun 01, 2026.
CONCORDBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Concord Biotech's board meeting on May 29, 2026 approved multiple items including audited FY2026 financial results showing revenue of Rs. 1,05,507 lakhs (down from Rs. 1,20,009 lakhs in FY25) and profit after tax of Rs. 26,327 lakhs (down from Rs. 37,296 lakhs). The company recommended dividend of Rs. 7.55 per share for FY26, subject to shareholder approval. Mrs. Ekta Gupta has been appointed as Additional Independent Director effective June 1, 2026 for a 5-year term subject to shareholder approval. She holds an MBA in Finance from Cardiff University and is currently a Director at Sanghi Polymers Private Limited with prior experience at Deutsche Bank. The appointment is not related to any existing directors and she holds no shares in the company.
The appointment of an experienced independent director strengthens board governance. However, the significant decline in revenue and profit (around 12% and 29% respectively) compared to FY25 may concern investors despite the dividend payout.